Cipla Ltd
Ticker: CIPLA
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
1558.70
Market Cap
125906.44
Debt/Equity
0.0140
ROE %
18.152
PB
4.0240
Promoter %
29.127
Pledge %
0.000
1Y Rev Growth %
7.122
5Y Rev Growth %
10.206
NP Margin %
18.559
NP Margin 5Y Avg %
13.992
Trading Reference
1M Return %
-1.473
6M Return %
5.190
1Y Return %
-0.830
% Away 52W High
3.442
% Away 52W Low
16.757
Daily Volume
1638237
Investment Verdict
Hold
Score 65/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 40/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Cipla Ltd is currently trading near a key support level, with the 50-day EMA indicating a potential upward trend. If it breaks above the resistance level, there is a strong probability of a bullish move. However, if it falls below the support, a bearish trend may ensue.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
H
HDFC Asset Management Company Ltd
HDFC Asset Management Company Ltd shows decent fundamentals with consistent growth, but faces valuation challenges and competitive pressures.
View details
C
CG Power and Industrial Solutions Ltd
CG Power shows potential in a future-ready sector but faces challenges in growth consistency and profitability metrics.
View details
T
Tata Power Company Ltd
Tata Power has a decent outlook with growth potential in the renewable sector, but faces challenges in profitability and competition.
View details
P
Punjab National Bank
Punjab National Bank shows potential but faces significant challenges in profitability and market sentiment, making it a risky investment at this time.
View details
B
Bank of Baroda Ltd
Bank of Baroda shows decent potential with moderate growth and profitability metrics, but faces challenges in execution and market sentiment.
View details
T
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals shows decent potential with a solid business model and growth prospects, but faces challenges in profitability and valuation metrics.
View details
S
Siemens Energy India Ltd
Siemens Energy India Ltd shows potential in a growing sector, but faces challenges in execution and profitability.
View details
S
Shriram Finance Ltd
Shriram Finance Ltd shows potential for growth but faces challenges in profitability and market competition. Caution is advised.
View details
M
Mazagon Dock Shipbuilders Ltd
Mazagon Dock Shipbuilders Ltd shows potential in a critical sector, but faces challenges in growth consistency and execution risks.
View details
B
Bosch Ltd
Bosch Ltd shows potential for growth with a solid business model, but faces challenges in profitability and valuation metrics.
View details
M
Muthoot Finance Ltd
Muthoot Finance Ltd shows decent fundamentals but faces challenges in profitability and valuation. Caution is advised.
View details
G
Gail (India) Ltd
Gail (India) Ltd shows potential in a growing sector, but faces challenges in growth consistency and valuation metrics.
View details
L
Lodha Developers Ltd
Lodha Developers Ltd presents a mixed outlook with significant risks, particularly in execution and market sentiment.
View details
M
Max Healthcare Institute Ltd
Max Healthcare shows potential for growth but faces challenges in profitability and valuation metrics.
View details
S
Siemens Ltd
Siemens Ltd shows a decent investment potential with strong growth prospects and a solid business model, but investors should be cautious of execution risks and market volatility.
View details
A
Apollo Hospitals Enterprise Ltd
Apollo Hospitals Enterprise Ltd shows a decent investment opportunity with strong growth potential, but valuation concerns and execution risks should be monitored.
View details
Business Overview
Cipla Ltd is a leading Indian pharmaceutical company dedicated to providing high-quality medicines and healthcare solutions. With a strong focus on innovation and accessibility, Cipla caters to a diverse range of therapeutic areas including respiratory, cardiovascular, and oncology. The company plays a crucial role in improving health outcomes for millions, making essential treatments affordable and available. Cipla's commitment to research and development ensures it remains at the forefront of the industry, positively impacting lives across India and beyond.
- Established leader in the pharmaceutical sector
- Wide range of therapeutic solutions
- Focus on affordability and accessibility
- Strong commitment to research and innovation
- Positive impact on public health
- Global presence with local expertise
Investment Thesis
Cipla Ltd stands out as a strong investment choice due to its credible promoter group, robust growth in digital services, and attractive valuation compared to peers. With a solid foundation and strategic initiatives, Cipla is well-positioned for long-term growth in the pharmaceutical sector.
- Strong promoter credibility enhances investor confidence.
- Significant growth potential in digital health services.
- Attractive valuation metrics compared to industry peers.
- Consistent financial performance and dividend history.
- Strategic focus on innovation and market expansion.
Opportunity vs Risk
Opportunities
- Strong pipeline of new drugs
- Growing demand for generic medicines
- Expansion into international markets
- Strategic partnerships with healthcare firms
Risks ⚠️
- Regulatory challenges in drug approvals
- Intense competition in generics
- Currency fluctuations affecting profits
- Rising raw material costs
Peer Perspective
Cipla Ltd trades at a discount to peers like Sun Pharma and Dr. Reddy's, reflecting concerns over margin stability. A sustained improvement in operational efficiency could trigger a rerating in its valuation.
Future Outlook
Cipla Ltd is well-positioned for growth, driven by strong product pipelines and expanding markets; however, successful execution and cost control will be crucial to fully capitalize on these opportunities.
AI FAQs for Retail Users
- Q: What does Cipla Ltd do?A: Cipla Ltd is a pharmaceutical company that develops and manufactures a wide range of medicines.
- Q: Is Cipla a good investment?A: Investment suitability depends on individual financial goals and market conditions; consider consulting a financial advisor.
- Q: What are the main products of Cipla?A: Cipla produces generic and branded medications, including respiratory, cardiovascular, and anti-infective drugs.
- Q: How is Cipla's performance in the market?A: Cipla's market performance varies; check recent financial reports and market analysis for updates.
- Q: What are the risks of investing in Cipla?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
📊 Stock Investment Checklist (100 Points)
Cipla Ltd • Updated: 2025-09-17 06:28:42
-
10BusinessHighCipla operates in the pharmaceutical sector, which is essential and has growth potential due to increasing healthcare needs.
-
10GrowthHighThe company has shown consistent revenue and profit growth over the past few years.
-
10ProfitabilityHighCipla maintains a healthy ROE and ROCE, with operating cash flow supporting net profits.
-
8ValuationHighValuation metrics like P/E and P/B are in line with industry averages, suggesting fair valuation.
-
7BalanceHighThe balance sheet shows manageable debt levels and adequate liquidity.
-
6GovernanceGoodPromoter holding is stable, but there are concerns about pledging.
-
5DriversGoodGrowth drivers include new product launches, but execution risks remain.
-
5TechnicalsGoodMarket sentiment is mixed, with some volatility in price action.
Final Score & Verdict
Score 68 / 100
• Decent
Cipla Ltd shows a decent investment profile with consistent growth and profitability, though some risks and governance concerns exist.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 68/100
- Governance: 80/100
- Market Confidence: 72/100